Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial

Published:March 08, 2019DOI:https://doi.org/10.1016/j.jaac.2019.01.015

      Objective

      To investigate cardiometabolic effects and their predictors in youths with first-episode psychosis (FEP) treated with quetiapine-extended release (ER) versus aripiprazole.

      Method

      Youths with FEP who were 12 to 17 years of age were randomized to quetiapine-ER or aripiprazole in the 12-week, double-blinded, Tolerability and Efficacy of Antipsychotics (TEA) trial. Primary outcome was change in body weight; secondary outcomes were changes in body mass index (BMI) and waist circumference (WC), blood pressure (BP), heart rate, and lipid and glucose metabolism parameters. Possible predictors of cardiometabolic changes were examined.

      Results

      Altogether, 113 patients (schizophrenia-spectrum disorders = 93%; age [mean ± SD] = 15.7 ± 1.4 years; male participants = 30.1%) were randomized to quetiapine-ER (n = 55) or aripiprazole (n = 58). Quetiapine-ER led to significant increases in body weight (4.88 kg, 95% CI = 3.92−5.83, p < .0001), BMI z-score (0.43, 95% CI = 0.33−0.53, p < .0001), and WC z-score (0.97, CI = 0.7−1.23, p < .0001). Changes were significantly smaller with aripiprazole (all between-group p values <.0001): body weight: 1.97 kg (CI = 0.97−2.97, p = .0001), BMI z-score: 0.10 (CI = −0.01 to 0.20, p = .0646), and WC z-score: 0.18 (CI = −0.09 to 0.45, p = .1968). Lipid and glucose metabolism parameters increased significantly at week 4 and week 12 only with quetiapine-ER (p range = 0.0001−0.037). Quetiapine-ER was associated with an increased occurrence of obesity, elevated blood lipids and hyperinsulinemia (p range = 0.004−0.039). Early weight gain, obesity, or type 2 diabetes in the family significantly predicted weight and BMI gain at week 12.

      Conclusion

      In youths with FEP, quetiapine-ER was associated with significantly greater weight gain and adverse changes in metabolic outcomes than was aripiprazole. Early weight gain must be addressed and family lifestyle factors taken into consideration when treating youths with antipsychotics.

      Clinical trial registration information

      Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA); https://clinicaltrials.gov; NCT01119014.

      Key words

      To read this article in full you will need to make a payment

      References

        • Chang C.K.
        • Hayes R.D.
        • Perera G.
        • et al.
        Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London.
        PLoS One. 2011; 6: e19590
        • Laursen T.M.
        • Wahlbeck K.
        • Hallgren J.
        • et al.
        Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries.
        PLoS One. 2013; 8: e67133
        • Osby U.
        • Correia N.
        • Brandt L.
        • Ekbom A.
        • Sparen P.
        Mortality and causes of death in schizophrenia in Stockholm County, Sweden.
        Schizophr Res. 2000; 45: 21-28
        • Fors B.M.
        • Isacson D.
        • Bingefors K.
        • Widerloov B.
        Mortality among persons with schizophrenia in Sweden: an epidemiological study.
        Nordic J Psychiatry. 2007; 61: 252-259
        • Laursen T.M.
        • Munk-Olsen T.
        • Vestergaard M.
        Life expectancy and cardiovascular mortality in persons with schizophrenia.
        Curr Opin Psychiatry. 2012; 25: 83-88
        • Nordentoft M.
        • Wahlbeck K.
        • Hallgren J.
        • et al.
        Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.
        PLoS One. 2013; 8: e55176
        • Correll C.U.
        • Lencz T.
        • Malhotra A.K.
        Antipsychotic drugs and obesity.
        Trends Mol Med. 2011; 17: 97-107
        • Ryan M.C.M.
        • Collins P.
        • Thakore J.H.
        Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.
        Am J Psychiatry. 2003; 160: 284-289
        • Meyer J.
        • Koro C.E.
        • L'Italien G.J.
        The metabolic syndrome and schizophrenia: a review.
        Int Rev Psychiatry. 2005; 17: 173-180
        • De Hert M.
        • Detraux J.
        • van Winkel R.
        • Yu W.
        • Correll C.U.
        Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
        Nat Rev Endocrinol. 2012; 8: 114-126
        • Kranzler H.N.
        • Cohen S.D.
        Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management.
        Child Adolesc Psychiatr Clin North Am. 2013; 22: 727-744
        • Clemmensen L.
        • Vernal D.L.
        • Steinhausen H.C.
        A systematic review of the long-term outcome of early onset schizophrenia.
        BMC Psychiatry. 2012; 12: 150
        • Remschmidt H.
        • Theisen F.M.
        Schizophrenia and related disorders in children and adolescents.
        J Neural Transm Suppl. 2005; : 121-141
        • De Hert M.
        • Dobbelaere M.
        • Sheridan E.M.
        • Cohen D.
        • Correll C.U.
        Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice.
        Eur Psychiatry. 2011; 26: 144-158
        • Foley D.L.
        • Morley K.I.
        Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.
        Arch Gen Psychiatry. 2011; 68: 609-616
        • Hasnain M.
        • Fredrickson S.K.
        • Vieweg W.V.
        • Pandurangi A.K.
        Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
        Curr Diabetes Rep. 2010; 10: 209-216
        • Maayan L.
        • Correll C.U.
        Management of antipsychotic-related weight gain.
        Expert Rev Neurother. 2010; 10: 1175-1200
        • Raedler T.J.
        Cardiovascular aspects of antipsychotics.
        Curr Opin Psychiatry. 2010; 23: 574-581
        • Stahl S.M.
        • Mignon L.
        • Meyer J.M.
        Which comes first: atypical antipsychotic treatment or cardiometabolic risk?.
        Acta PsychiatrScand. 2009; 119: 171-179
        • Galling B.
        • Correll C.U.
        Do antipsychotics increase diabetes risk in children and adolescents?.
        Expert Opin Drug Saf. 2015; 14: 219-241
        • Galling B.
        • Roldan A.
        • Nielsen R.E.
        • et al.
        Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis.
        JAMA Psychiatry. 2016; 73: 247-259
        • Olfson M.
        • Blanco C.
        • Liu S.M.
        • Wang S.
        • Correll C.U.
        National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.
        Arch Gen Psychiatry. 2012; 69: 1247-1256
        • Panagiotopoulos C.
        • Ronsley R.
        • Elbe D.
        • Davidson J.
        • Smith D.H.
        First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.
        J Can Acad Child AdolescPsychiatry. 2010; 19: 124-137
        • Steinhausen H.C.
        • Bisgaard C.
        Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark.
        Acta Psychiatr Scand. 2014; 129: 221-231
        • Halfdanarson O.
        • Zoega H.
        • Aagaard L.
        • et al.
        International trends in antipsychotic use: a study in 16 countries, 2005-2014.
        Eur Neuropsychopharmacol. 2017; 27: 1064-1076
        • Cohen D.
        • Bonnot O.
        • Bodeau N.
        • Consoli A.
        • Laurent C.
        Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
        J Clin Psychopharmacol. 2012; 32: 309-316
        • Correll C.U.
        • Manu P.
        • Olshanskiy V.
        • Napolitano B.
        • Kane J.M.
        • Malhotra A.K.
        Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
        JAMA. 2009; 302: 1765-1773
        • Findling R.L.
        • Pathak S.
        • Earley W.R.
        • Liu S.
        • DelBello M.
        Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.
        J Child Adolesc Psychopharmacol. 2013; 23: 490-501
        • Shaw J.A.
        • Lewis J.E.
        • Pascal S.
        • et al.
        A study of quetiapine: efficacy and tolerability in psychotic adolescents.
        J Child Adolesc Psychopharmacol. 2001; 11: 415-424
        • Arango C.
        • Robles O.
        • Parellada M.
        • et al.
        Olanzapine compared to quetiapine in adolescents with a first psychotic episode.
        Eur Child Adolesc Psychiatry. 2009; 18: 418-428
        • Schimmelmann B.G.
        • Mehler-Wex C.
        • Lambert M.
        • et al.
        A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
        J Child Adolesc Psychopharmacol. 2007; 17: 768-778
        • Masi G.
        • Milone A.
        • Veltri S.
        • Iuliano R.
        • Pfanner C.
        • Pisano S.
        Use of quetiapine in children and adolescents.
        Paediatr Drugs. 2015; 17: 125-140
        • Arango C.
        • Giraldez M.
        • Merchan-Naranjo J.
        • et al.
        Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients.
        J Am Acad Child Adolesc Psychiatry. 2014; 53: 1179-1190
        • Nielsen R.E.
        • Laursen M.F.
        • Lammers Vernal D.
        • et al.
        Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study.
        J Am Acad Child Adolesc Psychiatry. 2014; 53: 971-979
        • Pillinger T.
        • Beck K.
        • Gobjila C.
        • Donocik J.G.
        • Jauhar S.
        • Howes O.D.
        Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis.
        JAMA Psychiatry. 2017; 74: 261-269
        • Stentebjerg-Olesen M.
        • Pagsberg A.K.
        • Fink-Jensen A.
        • Correll C.U.
        • Jeppesen P.
        Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review.
        J Child Adolesc Psychopharmacol. 2016; 26: 410-427
        • Cervellione K.L.
        • Burdick K.E.
        • Cottone J.G.
        • Rhinewine J.P.
        • Kumra S.
        Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome.
        J Am Acad Child Adolesc Psychiatry. 2007; 46: 867-878
        • Helgeland M.I.
        • Torgersen S.
        Stability and prediction of schizophrenia from adolescence to adulthood.
        Eur Child Adolesc Psychiatry. 2005; 14: 83-94
        • Kendall T.
        • Hollis C.
        • Stafford M.
        • Taylor C.
        • Guideline Development Group
        Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance.
        BMJ. 2013; 346: f150
        • Roerig J.L.
        • Steffen K.J.
        • Mitchell J.E.
        Atypical antipsychotic-induced weight gain: insights into mechanisms of action.
        CNS Drugs. 2011; 25: 1035-1059
        • Nash A.I.
        Crosstalk between insulin and dopamine signaling: a basis for the metabolic effects of antipsychotic drugs.
        J Chem Neuroanat. 2017; 83-84: 59-68
        • Manu P.
        • Correll C.U.
        • Wampers M.
        • et al.
        Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
        Schizophr Res. 2013; 143: 358-362
        • Jensen K.G.
        • Correll C.U.
        • Ruda D.
        • et al.
        Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial.
        J Clin Psychiatry. 2017;
        • Pagsberg A.K.
        • Jeppesen P.
        • Klauber D.G.
        • et al.
        Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
        Lancet Psychiatry. 2017; 4: 605-618
        • Pagsberg A.K.
        • Jeppesen P.
        • Klauber D.G.
        • et al.
        Quetiapine versus aripiprazole in children and adolescents with psychosis─protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
        BMC Psychiatry. 2014; 14: 199
        • World Health Organization
        The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.
        World Health Organization, Geneva1992
        • Kaufman J.
        • Birmaher B.
        • Brent D.
        • et al.
        Schedule for Affective Disorders and Schizophrenia for School-Age Children−Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.
        J Am Acad Child Adolesc Psychiatry. 1997; 36: 980-988
        • Kay S.R.
        • Fiszbein A.
        • Opler L.A.
        The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
        Schizophr Bull. 1987; 13: 261-276
        • Sharma S.
        • Fleming S.E.
        Use of HbA(1C) testing to diagnose pre-diabetes in high risk African American children: a comparison with fasting glucose and HOMA-IR.
        Diabetes Metab Synd. 2012; 6: 157-162
        • Singh B.
        • Saxena A.
        Surrogate markers of insulin resistance: a review.
        World J Diabetes. 2010; 1: 36-47
        • Lee J.M.
        • Okumura M.J.
        • Davis M.M.
        • Herman W.H.
        • Gurney J.G.
        Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study.
        Diabetes Care. 2006; 29: 2427-2432
        • Kjøller M.
        • Juel K.
        • Kamper-Jørgensen F.
        • et al.
        Folkesundhedsrapporten Danmark 2007.
        Statens Institut for Folkesundhed, Odense, Denmark2007
        • DUN
        Dansk Uddannelses Nomenklatur.
        in: Statistics Denmark. Undervisningsministeriet (Ministry of Education), København, Denmark2006
        • Hafner H.
        • Riecher-Rossler A.
        • Hambrecht M.
        • et al.
        IRAOS: an instrument for the assessment of onset and early course of schizophrenia.
        Schizophr Res. 1992; 6: 209-223
        • World Health Organization
        WHO fact sheet: cardiovascular diseases (CVDs). 2013.
        (Available at:)
        • Zimmet P.
        • Alberti K.G.
        • Kaufman F.
        • et al.
        The metabolic syndrome in children and adolescents─an IDF consensus report.
        Pediatr Diabetes. 2007; 8: 299-306
        • Brannsether B.
        • Roelants M.
        • Bjerknes R.
        • Juliusson P.B.
        Waist circumference and waist-to-height ratio in Norwegian children 4-18 years of age: reference values and cut-off levels.
        Acta Paediatr. 2011; 100: 1576-1582
        • Tinggaard J.
        • Aksglaede L.
        • Sorensen K.
        • et al.
        The 2014 Danish references from birth to 20 years for height, weight and body mass index.
        Acta Paediatr. 2014; 103: 214-224
        • Leucht S.
        • Cipriani A.
        • Spineli L.
        • et al.
        Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
        Lancet. 2013; 382: 951-962
        • Pagsberg A.K.
        • Tarp S.
        • Glintborg D.
        • et al.
        Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis.
        J Am Acad Child Adolesc Psychiatry. 2017; 56: 191-202
        • Krause M.
        • Zhu Y.
        • Huhn M.
        • et al.
        Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis.
        Eur Neuropsychopharmacol. 2018; 28: 659-674
        • Vandenberghe F.
        • Saigi-Morgui N.
        • Delacretaz A.
        • et al.
        Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
        Pharmacogenet Genomics. 2016; 26: 547-557
        • Simon V.
        • van Winkel R.
        • De Hert M.
        Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
        J Clin Psychiatry. 2009; 70: 1041-1050
        • Vandenberghe F.
        • Gholam-Rezaee M.
        • Saigi-Morgui N.
        • et al.
        Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
        J Clin Psychiatry. 2015; 76: e1417-e1423
        • Correll C.U.
        • Sikich L.
        • Reeves G.
        • Riddle M.
        Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?.
        Am J Psychiatry. 2013; 170: 947-952
        • Zhang J.P.
        • Lencz T.
        • Zhang R.X.
        • et al.
        Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis.
        Schizophr Bull. 2016; 42: 1418-1437
        • Baker J.L.
        • Olsen L.W.
        • Sorensen T.I.
        Childhood body-mass index and the risk of coronary heart disease in adulthood.
        N Engl J Med. 2007; 357: 2329-2337
        • Tirosh A.
        • Shai I.
        • Afek A.
        • et al.
        Adolescent BMI trajectory and risk of diabetes versus coronary disease.
        N Engl J Med. 2011; 364: 1315-1325
        • Park M.H.
        • Falconer C.
        • Viner R.M.
        • Kinra S.
        The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review.
        Obes Rev. 2012; 13: 985-1000
        • Murphy A.L.
        • Gardner D.M.
        • Kisely S.
        • Cooke C.
        • Kutcher S.P.
        • Hughes J.
        Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain.
        ISRN Obesity. 2013; 2013: 390130